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Abstract
Background: Vertical transmission can result in neonatal infection and disease. Reducing the transmission of bacterial
pathogens from mother to infant may be an effective means of preventing neonatal infection, including bacterial
conjunctivitis.
Methods: In a double-blind, randomized trial, we assessed the effect of administering a single dose of oral azithromycin
to women in labour on bacterial colonization of the neonate. A reduction in purulent neonatal conjunctivitis was a
secondary objective of the trial. Ocular samples were collected from the lower fornix of infants presenting with clinical
signs of purulent conjunctivitis during the first eight weeks of life. Incidence of purulent conjunctivitis was compared
between trial arms. Bacterial infection was assessed using PCR and incidence of purulent conjunctivitis due to bacteria
was also compared between arms.
Results: Forty of 843 infants (4.7%) presented clinical signs of purulent conjunctivitis. No significant difference in incidence
of purulent conjunctivitis was seen between azithromycin and placebo arms [4.3% (18/419) versus 5.2% (22/424), OR = 0.82,
95% CI (0.44,1.54), p= 0.628]. S. aureus was the most commonly identified pathogen, detected in 38% of cases. Incidence of
purulent-conjunctivitis due to bacterial infection was lower in the azithromycin arm [1.2% (5/419) versus 3.8%
(16/424), OR = 0.31, 95% CI (0.12–0.82), p = 0.025)]. The incidence of gram-positive bacteria was also lower in
the azithromycin arm [1.0% (4/419) versus 3.3% (14/424), OR = 0.28, 95%CI (0.10–0.82), p = 0.029].
Conclusions: Oral azithromycin given to women during labour may have the potential to reduce the incidence of
bacterial neonatal conjunctivitis.
Trial registration: ClinicalTrials.gov, identifier NCT01800942, registration date 26 Feb 2013.
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Background
Ocular bacterial infection in neonates often results from
vertical transmission, from mother to child, during deliv-
ery. The most common causes are Neisseria gonorrhoeae
and Chlamydia trachomatis, although infection can also
be attributed to other bacteria, including Staphylococcus
aureus. Prenatal screening and treatment of expectant
mothers is an effective means of preventing neonatal
infection [1, 2]. Because bacterial conjunctivitis can give
rise to complications including corneal ulceration,
perforation of the globe and visual impairment, many
countries also recommend the use of ocular antibiotic
ointment at birth as a preventive measure [3].
Vertical transmission during delivery can also result in
invasive disease, including neonatal sepsis, which is an
important cause of death in this age group [4]. S. aureus
and Streptococcus pneumoniae are the most common
cause of sepsis in African infants [5]. As asymptomatic
carriage precedes bacterial invasion, interventions aimed
at reducing carriage may provide an effective means of
preventing disease. As an example, prenatal screening
for group B streptococcus and the administration of
intravenous antibiotics during labour have greatly
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reduced colonization and invasive neonatal disease in
North American and Europe [6, 7]. However, this ap-
proach is not feasible in many low-income settings where
simpler and more cost effective solutions for preventing
neonatal sepsis are urgently needed. In The Gambia, West
Africa, a recent randomized, double-blind trial (Preg-
nAnZI) was conducted in which women were randomized
to receive azithromycin or placebo during labour [8, 9].
Azithromycin was chosen because it can be given orally,
has significant effects with a single dose and does not re-
quire transport and storage in a cold chain. The aim of
the trial was to reduce maternal carriage of S. aureus, S.
pneumoniae and group B streptococcus during delivery
thereby preventing vertical transmission and subsequent
colonization of the neonates.
Trial results indicated a significant reduction in the car-
riage of all study bacteria in the vaginal swabs, breast milk
and nasopharyngeal samples of mothers in the azithromycin
arm as compared to the placebo arm during the first four
weeks following delivery. As hypothesised, bacterial carriage
was also reduced in the nasopharynx of neonates whose
mothers received the intervention compared to those who
received placebo; this reduction was maintained throughout
the first month of life [9]. A reduction in disease was also
documented in mothers who received azithromycin and in
their neonates indicating a clinical benefit of treatment [10].
A secondary objective of the PregnAnZI trial was to
assess the effect of giving azithromycin during labour on
purulent neonatal conjunctivitis. Herein, we report the
incidence of purulent conjunctivitis and purulent
conjunctivitis associated with bacterial infection in the
trial and its aetiology. We also report a risk factors analysis
for bacterial conjunctivitis among study participants.
Methods
Study design
This was a phase III, double-blind, placebo controlled,
randomized trial. The trial protocol and results of the
primary endpoints have already been published [8, 9].
Briefly, 829 women attending the study health facility
during labour and who had previously given informed
consent were randomized to receive an oral dose of 2 g
of azithromycin or placebo. Mothers and their neonates
were sampled throughout the first four weeks following
delivery to determine the effect of treatment on vaginal,
nasopharyngeal and breast milk carriage of S.
pneumoniae, S. aureus and group B streptococcus. The
primary trial end-point was nasopharyngeal carriage of
the study bacteria in the neonate, at day six following
delivery. As part of standard care in the country,
newborns received tetracycline ointment in the eyes
before hospital discharge. Active and passive follow-up
was conducted for eight weeks after delivery.
Sample collection
An ocular swab was collected from infants presenting
with purulent conjunctivitis during the first eight weeks
of life. Samples were collected from the lower fornix
using a sterile cotton swab and kept on wet ice at the
clinic. All samples were transported to the laboratory
within 8 h of collection for storage at −70 °C until
further processing.
DNA extraction and PCR
DNA was extracted using the QIAamp DNA Mini Kit
(QIAGEN, Germany). The presence of DNA from S.
pneumoniae, S. aureus, Moraxella catarrhalis, Hae-
mophilus influenzae, C. trachomatis and N. gonorrhoeae
was assayed using the FTD SPn/Staph/MC/Hi and Vagi-
nal Swab kits (Fast-track Diagnostics, Luxembourg) run
on a RotorGene 6000 real-time PCR cycler (QIAGEN,
Germany). Samples were further tested for the presence
of C. trachomatis DNA using droplet-digital PCR ac-
cording to a previously published method [11]. Labora-
tory staff was blinded to allocation arm.
Outcomes
Pre-defined, secondary endpoints of the PregnAnZI trial
included the proportion of newborns with at least one epi-
sode of purulent conjunctivitis and ocular C. trachomatis
infection within the first week of life, the first four weeks
of life and during the eight weeks of the follow-up period
[8]. Purulent conjunctivitis caused by bacterial pathogens
other than C. trachomatis was not a stated outcome of the
trial and was investigated ad hoc.
Statistical analysis
Incidence of purulent conjunctivitis and purulent
conjunctivitis due to defined bacterial pathogens was
compared between arms. Due to the small numbers of
cases seen, only the endpoint at eight weeks follow-up
was considered, rather than assessing the three individ-
ual time-points specified in the original protocol [8].
Odds ratios and exact p-values for these comparisons
were calculated using the cs command in Stata. Risk
factors for bacterial conjunctivitis were analysed using
data from both trial arms combined and from the
control arm only.
Ethical review
The trial was approved by the Joint Gambian Government/
Medical Research Council Ethics Committee. An
independent Data Safety Monitoring Board monitored the
data quality and treatment safety. Written, informed
consent was obtained from all women during visits to the
antenatal clinic.
Burr et al. BMC Infectious Diseases  (2017) 17:799 Page 2 of 6
Results and discussion
Study participants
A total of 829 mothers and their offspring were
recruited. Baseline characteristics were similar between
intervention and control arms (Table 1).
Incidence of purulent conjunctivitis
Eight-hundred-forty-three babies were delivered includ-
ing 13 stillbirths. Forty infants (4.7%, 40/843) presented
with purulent conjunctivitis during the eight-week
follow-up period. Three infants were sampled on two
separate occasions (1 in the azithromycin and 2 in the
placebo arm). The median age at the onset of conjunc-
tivitis was 4 days (IQR 2 to 8). Age of onset was missing
for 6 cases of conjunctivitis. The median duration of
clinical signs was 7 days (IQR 4 to 9). No difference
was seen in the numbers of infants presenting with
purulent conjunctivitis in the azithromycin (4.3%, 18/
419) versus placebo (5.2%, 22/424) arm [OR = 0.82,
95%CI (0.44–1.54), p = 0.628] (Table 2).
Aetiology
S. aureus was the most common bacteria, being identi-
fied in 38% (16/42) of the swabs tested (Table 2); one
sample was missing in the laboratory analysis. This find-
ing is consistent with the results of other studies in West
Africa (Togo and Nigeria) that have reported S. aureus
is a leading cause of bacterial neonatal conjunctivitis in
this region [12, 13]. No significant difference was seen in
the incidence of S. aureus infection between trial arms
with an overall incidence of 1.0% (4/419) in the azithro-
mycin and 2.8% (12/424) in the placebo arm [OR = 0.33,
95%CI (0.11–0.98), p = 0.074].
The incidence of infection with S. pneumoniae, M.
catarrhalis, H. influenzae and N. gonorrhoeae was low.
Although positive results for S. pneumoniae, M.
catarrhalis and H. influenzae were only obtained in the
placebo arm, no statistically significant difference was
seen between trial arms, possibly because of the low
numbers of infections detected. No sample was positive
for C. trachomatis. While there is no recent data on uro-
genital C. trachomatis infection in The Gambia, our re-
sults are in keeping with historical data that indicates
prevalence of infection is low [14, 15]. Four swabs, all in
the placebo arm, showed evidence of infection with more
than one bacterium; 3 co-infected with 2 bacteria and 1
with 3 bacteria. All 3 samples positive for H. influenzae
were co-infected with another bacteria (S. aureus; S.
pneumoniae and M. catarrhalis; S. pneumoniae).
Table 1 Baseline characteristics of study participants
Mothers Azithromycin arm (N = 414) Placebo arm (N = 415)
Characteristics n (%) n (%)
Age (Median, IQR) 26.0 (22.0,30.0) 25.0 (22.0,30.0)
Ethnicity Madinka 161 (40.1) 187 (45.8)
Fula 77 (19.2) 64 (15.7)
Jola 68 (17.0) 56 (13.7)
Other 95 (23.7) 101 (24.8)
Season of deliverya Rainy 141 (34.1) 143 (34.5)
Mode of delivery Vaginal 404 (97.6) 410 (98.8)
Caesarean 10 (2.4) 5 (1.2)
Multiple pregnancy Yes 5 (1.2) 9 (2.2)
Hours from rupture of membrane to deliveryb (Median, IQR) 0.4 (0.1,1.8) 0.3 (0.1,1.3)
Newborns Azithromycin arm (N = 419) Placebo arm (N = 424)
Characteristics n (%) n (%)
Gender Female 207 (49.4) 198 (46.7)
Apgar score at birth 0–6 14 (3.3) 11 (2.6)
7–10 402 (96.6) 408 (97.4)
Weightc (Median, IQR) 3.1 (2.8,3.5) 3.1 (2.9,3.4)
Outcomes
Stillbirths 7 (1.7) 6 (1.4)
Deaths during the follow up period 8 (1.9) 8 (1.9)
aRainy season: children born June to October
bTime of rupture of membranes is missing in n = 441 (230 in the azithromycin and 211 in the placebo arm)
cWeight missing in n = 2 (both in the placebo arm)
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Overall, the incidence of purulent bacterial conjunctivitis
was lower in the azithromycin arm [1.2% (5/419) versus
3.8% (16/424), OR = 0.31, 95% CI (0.12–0.82), p = 0.025)]
suggesting a beneficial effect of treatment. The incidence
of conjunctivitis associated with gram-positive bacteria was
also lower in the intervention arm [1.0% (4/419) versus
3.3% (14/424), OR = 0.28, 95%CI (0.10–0.82), p = 0.029]
(Table 2). The incidence of gram-negative bacteria was
lower in the intervention arm however this difference was
not statistically significant [0.2% (1/419) versus 1.4% (6/
424), OR = 0.17, 95% CI (0.00–1.06), p = 0.123].
Risk factors
Vaginal colonization of the mother with any of the trial
study bacteria (S. aureus, S. pneumoniae and group B
streptococcus) prior to azithromycin administration was
not a risk factor for ocular infection in the neonate (both
trial arms, OR = 1.36, 95%CI 0.54–3.41, p = 0.468; pla-
cebo arm only, OR = 1.51, 95%CI 0.54–4.25, p = 0.412)
(Table 3). These findings however are limited as our ana-
lysis of ocular swabs targeted more pathogens than the
three study bacteria that were analysed in the vaginal
swabs. Recto-vaginal swabs from mothers may also have
yielded a better comparison than vaginal swabs alone.
Differences in risk of neonatal bacterial conjunctivitis
were not significant among infants who received
tetracycline ointment in the eye at birth compared to those
who did not although odds ratios were lower for those who
received ointment (both trial arms, OR = 0.79, 95%CI
0.23–2.75, p = 0.728; placebo arm only, OR = 0.52, 95%CI
0.14–1.91, p = 0.404) (Table 3). While other topical
antimicrobial agents are available for use in neonates,
evidence suggests that prophylaxis with tetracycline oint-
ment does result in better outcomes in comparison to
others such as povidone-iodine or erythromycin [16, 17].
Premature rupture of the membranes, which is a risk factor
for conjunctivitis in the low-income setting of Malawi [18],
was not a risk factor in The Gambia (both trial arms, OR =
1.12, 95%CI 0.47–2.68, p = 0.829; placebo arm only, OR =
1.59, 95%CI 0.57–4.45, p = 0.450) (Table 3).
Limitations
The majority of infants in the trial received ocular
tetracycline ointment after delivery, as is standard care
in The Gambia. This may have lowered incidence of
infection or modified the distribution of pathogens
thereby impacting our endpoint. Our study is also lim-
ited by statistical power, as the trial was not designed to
detect differences in the incidence of conjunctivitis or
bacterial conjunctivitis between study arms. While the
results showed a trend of lower incidence in the azithro-
mycin arm for almost all bacteria assayed, significant re-
sults were obtained only when grouping all purulent
bacterial conjunctivitis and conjunctivitis associated with
gram-positive bacteria. The majority of samples collected
from the azithromycin arm were negative for all the
bacteria assayed suggesting conjunctivitis in these infants
may have been chemical or viral in nature. However, our
panel focused only on the major causes of bacterial con-
junctivitis in neonates. It is possible that some cases
could have been due to less common bacteria, yet there
is no reason to believe that any other bacteria would
have been more prevalent in the azithromycin arm. The
limited power also extends to the risk factor analysis and
may explain why tetracycline ointment or the premature
rupture of membranes were not associated with
conjunctivitis.
Ocular swabs were collected in the absence of trans-
port media for the detection of C. trachomatis DNA by
molecular means, as purulent conjunctivitis with C.
trachomatis infection was a pre-specified outcome of the
trial. This prevented us from evaluating other bacterial
Table 2 Incidence of bacterial conjunctivitis reported by trial arm
Characteristic Azithromycin arm (N = 419) n (%) Placebo arm (N = 424) n (%) OR (95% CI) p-value
Purulent discharge 18 (4.3) 22 (5.2) 0.82 (0.44,1.54) 0.628
Any bacteria detected 5 (1.2) 16 (3.8) 0.31 (0.12,0.82) 0.025
Any gram-positive 4 (1.0) 14 (3.3) 0.28 (0.10,0.82) 0.029
S. aureus 4 (1.0) 12 (2.8) 0.33 (0.11,0.98) 0.074
S. pneumoniae 0 (0.0) 2 (0.5) 0.00 (0.00,1.94) 0.499
Any gram-negative 1 (0.2) 6 (1.4) 0.17 (0.00,1.06) 0.123
H. influenzae 0 (0.0) 3 (0.7) 0.00 (0.00,1.29) 0.249
M. catarrhalis 0 (0.0) 3 (0.7) 0.00 (0.00,1.29) 0.249
N. gonorrhoeae 1 (0.2) 1 (0.2) 1.01 (0.00, NA) 1.00
C. trachomatis 0 (0.0) 0 (0.0) – –
Bacterial co-infectiona 0 (0.0) 4 (0.9) 0.00 (0.00,0.97) 0.124
aBacterial co-infections: (i) S. aureus and H. influenzae; (ii) S. pneumoniae and H. influenzae; (iii) S. aureus and N. gonohorreae (iv) M. catarrhalis, S. pneumoniae and
H. influenzae
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infection by routine culture. However, PCR is generally
considered more sensitive than conventional bacteriological
techniques so we do not anticipate this adversely impacted
our results.
Conclusions
While numbers were small, our data suggest
azithromycin given in labour may provide a means of
decreasing the risk of ocular bacterial infection in the
neonate. Larger scale trials to determine the impact
of azithromycin treatment in labour on neonatal
sepsis are currently underway. If these studies show a
benefit, there may be a case for recommending this
intervention for deliveries as a means of decreasing
neonatal mortality.
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Table 3 Risk factors for neonatal bacterial eye infection
Characteristic Both trial arms Placebo arm only
N n (%) OR (95%CI) p-value N n (%) OR (95%CI) p-value
>18 h membrane rupture to birth
No 384 2.3 1 205 2.9 1
Yes 459 2.6 1.12 (0.47,2.68) 0.829 219 4.6 1.59 (0.57,4.45) 0.45
Gender
Female 405 1.7 1 198 2.5 1
Male 438 3.2 1.88 (0.75,4.70) 0.191 226 4.9 1.97 (0.67,5.79) 0.307
Apgar score
0 12 0.0 NA 6 0.0 NA
1–6 13 0.0 NA 5 0.0 NA
7–10 810 2.6 NA 1 408 3.9 NA 1
Low birth-weight (<2.5 kg)
No 786 2.5 1 392 3.8 1
Yes 55 1.8 0.71 (0.09,5.39) 1 30 3.3 0.87 (0.11,6.79) 1
Bacteria in the vaginal swab prior to intervention
No 615 2.3 1 302 3.3 1
Yes 228 3.1 1.36 (0.54,3.41) 0.468 122 4.9 1.51 (0.54,4.25) 0.412
Season
Dry 557 2.0 1 280 2.9 1
Wet 286 3.5 1.80 (0.75,4.29) 0.242 144 5.6 2.00 (0.73,5.44) 0.184
Tetracycline at birth
No 99 3.0 1 47 6.4 1
Yes 743 2.4 0.79 (0.23,2.75) 0.728 377 3.4 0.52 (0.14,1.91) 0.404
Mothers’ years of schooling
< 1 year 424 2.6 1 210 3.8 1
1+ years 398 2.5 0.97 (0.41,2.30) 1 203 3.9 1.04 (0.38,2.81) 1
Ethnicity
Madinka 352 2.3 1 189 3.7 1 0.691
Wollof 94 1.1 0.46 (0.06,3.74) 47 2.1 0.57 (0.07,4.71) 0.691
Jola 127 5.5 2.51 (0.89,7.06) 59 6.8 1.89 (0.53,6.70) 0.691
Fula 144 2.8 1.23 (0.36,4.15) 66 4.5 1.24 (0.31,4.93) 0.691
Other 106 0.9 0.41 (0.05,3.31) 0.23 56 1.8 0.47(0.06,3.93) 0.691
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